Cancer Biology
Cancer Biology Programme
Our cancer biology program focusses on advancing the understanding of carcinogenesis and cancer progression, with the aim of translating scientific discoveries into clinical applications. The programme encompasses three main themes:
- Cancer Biomarker Discovery and Molecular Therapeutic Targets: investigating the functional roles of specific biological markers and evaluating their utility as cancer biomarkers and therapeutic targets.
- RNA Editing and Cancer Development: exploring alterations in the cancer transcriptome and their implications for cancer initiation and progression.
- Mechanisms of Tumorigenesis: elucidating signaling pathways involved in oncogenesis, particularly JAK/Stat pathway.
Our interdisciplinary research approaches include molecular genetics, genomics, cell biology, chemistry, proteomics, computational biology, and imaging modalities. We actively collaborate from with:
- Cancer Science Institute
- Institute of Molecular Cell Biology
- Temasek Life Sciences Laboratories
- National University Hospital
- Singapore General Hospital
- Nanyang Technological University
- Hong Kong University
- RIKEN Institute (Japan)
- Imperial College (United Kingdom)
- Münster University Hospital (Germany)
- New York University (United States)
- Cincinnati Children’s Hospital Medical Center (United States)
- Baylor University Medical Center (United States)
NUS Centre for Cancer Research (N2CR)
The NUS Centre for Cancer Research (N2CR), one of ten new Translational Research Programmes (TRPs) in the National University of Singapore’s Yong Loo Lin School of Medicine, is developing innovative new ways to detect, cure and prevent cancer by undertaking internationally leading fundamental research that advances the understanding of cancer, and translating these research discoveries into clinical practice to benefit patients. N2CR’s research is focused on understanding key genetic and epigenetic changes that drive the origin and progression of cancer in different tissues, particularly those forms prevalent in Asia; developing new therapies to target specific cancers in specific patients; and gain insights into the genetic and environmental variations that underlie cancer susceptibility.
N2CR is strategically organized to motivate interdisciplinary collaborations – spanning from bench to bedside and back again – to drive research in key areas. The N2CR empowers fundamental and clinical researchers from NUS Medicine, our core partners: the Cancer Science Institute of Singapore, and the National Cancer Institute of Singapore (NCIS) in the National University Health System (NUHS), to work together, alongside scientists and technologists from other disciplines, to address major scientific and clinical challenges. N2CR’s work is enabled by cancer site-specific resources which include the collection of patient samples and databases with clinical information. It is focused on three cross-cutting themes namely Tissue-Specific Carcinogenesis, Precision Cancer Medicine and Early Cancer Intervention, that promote fruitful interdisciplinary collaborations between fundamental researchers, enabling technologists and clinical investigators.
/img1.jpg)
/img2.jpg)
N2CR Members from Department of Anatomy: